Home » Newsletters » BioWorld Science

BioWorld Science

March 25, 2022

View Archived Issues

"Trojan horse" approach redirects tetanus immune response to tumors

Researchers unveil novel markers of GABA catabolism pathway abnormalities

Roche patents compounds for Gram-negative bacterial infections

German researchers divulge nitric oxide production inhibitors

Medshine Discovery presents new antifungal compounds

Gasherbrum Bio identifies GLP-1 receptor agonists

Aubrak Therapeutics patents new PROTACs for cancer

Regulus miR-155 inhibitors studied to treat ALS

Chugai gains access to Halozyme's ENHANZE drug delivery technology

BiondVax collaborates with Max Planck and UMG for development of NanoAbs

Insilico Medicine and EQRx enter drug discovery and development collaboration

PPARgamma isoforms have specific and separable roles in gene regulation and metabolism

Predictive Oncology validates Discovery 21 results

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...